N-[2-(4-Aminophenyl)ethyl]-adenosine - CAS 89705-21-5
Catalog number:
89705-21-5
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C18H22N6O4
Molecular Weight:
386.41
COA:
Inquire
Targets:
Adenosine Receptor
Description:
N6-[2-(4-Aminophenyl)ethyl]adenosine is a potent, non-selective adenosine A3 adenosine receptor agonist. It could enhance the protective activity of carbamazepine and the protective activity potentiates most likely through the A subtype of adenosine receptors at low doses. It also enhances the anticonvulsive effect of other antiepileptics via adenosine A1 receptors at higher doses. It has no significant effect on seizure parameters in amygdala-kindled rats in vivo. It is combined with antiepileptic drugs administered at doses ineffective in fully kindled rats.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Appearance:
White Solid
Synonyms:
APNEA;Adenosine, N6-2-(4-aminophenyl)ethyl;(2R,3R,4S,5R)-2-[6-[2-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
Solubility:
10 mM in DMSO
Storage:
2-8ºC
MSDS:
Inquire
Application:
N6-[2-(4-Aminophenyl)ethyl]adenosine could enhance the protective activity of carbamazepine. It also enhances the anticonvulsive effect of other antiepileptic.
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Quantity:
Milligrams-Grams
Boiling Point:
781.8±70.0 °C | Condition: Press: 760 Torr
Density:
1.65±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
InChIKey:
XTPOZVLRZZIEBW-SCFUHWHPSA-N
InChI:
InChI=1S/C18H22N6O4/c19-11-3-1-10(2-4-11)5-6-20-16-13-17(22-8-21-16)24(9-23-13)18-15(27)14(26)12(7-25)28-18/h1-4,8-9,12,14-15,18,25-27H,5-7,19H2,(H,20,21,22)/t12-,14-,15-,18-/m1/s1
Canonical SMILES:
C1=CC(=CC=C1CCNC2=NC=NC3=C2N=CN3C4C(C(C(O4)CO)O)O)N
1.Adenosine receptors mediate both contractile and relaxant effects of adenosine in main pulmonary artery of guinea pigs.
Szentmiklósi AJ1, Ujfalusi A, Cseppentö A, Nosztray K, Kovács P, Szabó JZ. Naunyn Schmiedebergs Arch Pharmacol. 1995 Apr;351(4):417-25.
In guinea pig main pulmonary artery precontracted with noradrenaline, adenosine exerted an initial phasic contraction followed by a tonic contraction and a slow relaxation. After selective blockade by 1,3-dipropyl-8-cyclopentylxanthine (DPCPX: 10 nM) of A1 receptors, adenosine only elicited a rapid relaxation. This initial response was characterized by use of adenosine (AR) and its analogues N6-cyclopentyl-adenosine (CPA), R-N6-phenylisopropyladenosine (R-PIA), 2-chloroadenosine (CADO), 5'-N-ethyl-carboxamidoadenosine(NECA), N6-2-(4-aminophenyl) ethyl adenosine (APNEA) and 2-p-((carboxyethyl)-phenethylamino)-5'-carboxamidoadenosine (CGS 21 680). The order of potency of the adenosine analogues for purine-induced phasic contraction was CPA > R-PIA > NECA = APNEA > AR > CGS 21 680 suggesting the involvement of activation of A1 type adenosine receptors in the contraction phase. DPCPX antagonized the CPA-induced contraction with a pA2 = 9.
2.The role of intraspinal adenosine A1 receptors in sympathetic regulation.
Peng SC1, Ho CM, Ho ST, Tsai SK, Su CK. Eur J Pharmacol. 2004 May 10;492(1):49-55.
Using a splanchnic nerve-spinal cord preparation in vitro, we have previously demonstrated that tonic sympathetic activity is generated from the thoracic spinal cord. Here, we sought to determine if adenosine receptors play a role in modulating this spinally generated sympathetic activity. Various adenosine analogs were applied. N6-Cyclopentyladenosine (CPA, adenosine A1 receptor agonist) and 5'-N-ethylcarboxamidoadenosine (NECA, adenosine A1/A2 receptor agonist) reduced, while N6-[2-(4-aminophenyl)ethyl]adenosine (APNEA, non-selective adenosine A3 receptor agonist) did not alter sympathetic activity. The inhibitory effect of CPA or NECA on sympathetic activity was reversed by 8-cyclopentyltheophylline (CPT, adenosine A1 receptor antagonist) or abolished by CPT pretreatment. In the presence of 3,7-dimethyl-1-propargylxanthine (DMPX, adenosine A2 receptor antagonist), sympathetic activity was still reduced by CPA or NECA. Sympathetic activities were not changed by applications of the more selective adenosine A2 or A3 receptor agonists or antagonists, including 4-[2-[[6-amino-9-(N-ethyl-beta-D-ribofuranuronamidosyl)-9H-purin-2-yl]amino]ethyl]benzenepropanoic acid (CGS21680), 4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol (ZM241385), 2-chloro-N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (Chloro-IB-MECA), and 3-ethyl-5-benzyl-2-methyl-4-phenylethynyl-6-phenyl-1,4-(+/-)-dihydropyridine-3,5-dicarboxylate (MRS1191).
3.Functional characterization of adenosine receptors in the nucleus tractus solitarius mediating hypotensive responses in the rat.
White PJ1, Rose'Meyer RB, Hope W. Br J Pharmacol. 1996 Jan;117(2):305-8.
1. The aim of this study was to characterize adenosine receptors located in the nucleus tractus solitarius (NTS) that mediate decreases in blood pressure in the anaesthetized rat. To determine the adenosine receptor subtype involved, a range of selective agonists and antagonists were studied and their relative potencies evaluated. 2. The rank order of agonist potency in inducing decreases in diastolic blood pressure was N6-cyclopentyladenosine (CPA) > N6-cyclohexyladenosine (CHA) > N-ethyl-carboxamidoadenosine (NECA) > or = 2-phenylaminoadenosine (CV1808) > 2-p-(carboxyethyl)phenethylamino-5' N-ethylcarboxamidoadenosine (CGS 21680) > N6-(2-(4-aminophenyl)ethyl)-adenosine (APNEA). 3. The hypotensive action of CPA following microinjection into the NTS was antagonized by i.v. infusions (50 micrograms kg-1 min-1) of adenosine receptor antagonists, 8-cyclopentyl-1,3 dipropylxanthine (DPCPX), 8-phenyltheophylline (8-PT), 8-(p-sulphophenyl)theophylline (8-SPT), and 1,3-dipropyl-8-N-(2-diethylamino)ethyl)-N methyl-4-(2,3,6,7-tetrahydro-2,6-dioxo) benzenesulphonamidexanthine (PD 115199).
4.Demonstration of both A1 and A2 adenosine receptors in DDT1 MF-2 smooth muscle cells.
Ramkumar V1, Barrington WW, Jacobson KA, Stiles GL. Mol Pharmacol. 1990 Feb;37(2):149-56.
Adenosine receptors of the A1 and A2 subtypes were characterized in membranes from DDT1 MF-2 smooth muscle cells. These cells possess a high density of A1 adenosine receptors (Bmax = 0.8-0.9 pmol/mg of protein), as measured by both agonist and antagonist radioligands. Agonists compete for [125I]N6-[2-(4-amino-3-iodophenyl)ethyl]-adenosine (A1 receptor-selective radioligand) binding with the following potency series: (R)-phenylisopropyladenosine [(R)-PIA] greater than 5'-N-ethylcarboxamide adenosine (NECA) greater than (S)-PIA, indicative of their interaction with A1 adenosine receptors. Agonist competition for [3H]8-(4-[[[(2-aminoethyl)amino]carbonyl)methyl)oxy]phenyl)-1, 3-dipropylxanthine [( 3H]XAC) (an antagonist radioligand for the A1 adenosine receptor) was described by a two-state model of 1.3 nM (high affinity state, KK) and 370 nM (low affinity state, KL), with 70% of the receptors in the high affinity state (RH). Addition of guanosine 5'-[beta, alpha-imido]triphosphate (100 microM) shifted the (R)-PIA competition curves to the right to lower affinities.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Adenosine Receptor Products


CVT5440
(CAS: 531506-64-6)

CVT5440 is a selective, high affinity A(2B) adenosine receptor antagonist. It may has the potential treatment of asthma and has good selectivity.

CAS 124431-80-7 CGS 21680 Hydrochloride

CGS 21680 Hydrochloride
(CAS: 124431-80-7)

CGS 21680 Hcl is an adenosine A2 receptor agonist with IC50 of 22 nM, exhibits 140-fold over A1 receptor.

CAS 377727-26-9 Sch412348

Sch412348
(CAS: 377727-26-9)

412348 is an adenosine A2A receptor antagonist with anti-Parkinsonian activity in both rodent andprimate animal models. Because of its high affinity for the ade...

CAS 155271-17-3 KF21213

KF21213
(CAS: 155271-17-3)

KF21213 is a highly selective ligand for mapping CNS adenosine A2A receptors. The Ki values of KF21213 were 3.0 nM for the adenosine A2A receptors and >10,000 n...

CAS 53885-35-1 Ticlopidine Hydrochloride

Ticlopidine Hydrochloride
(CAS: 53885-35-1)

Ticlopidine HCl is an P2 receptor inhibitor against ADP-induced platelet aggregation with IC50 of ~2 μM.

CAS 479-18-5 Dyphylline

Dyphylline
(CAS: 479-18-5)

Dyphylline is a xanthine derivative with bronchodilator and vasodilator effects.It is used in the treatment of respiratory disorders like asthma, cardiac dyspne...

CAS 313348-27-5 Regadenoson

Regadenoson
(CAS: 313348-27-5)

Regadenoson, as a coronary vasodilator it is a selective A2A adenosine receptor agonist in myocardial imaging.

CAS 121241-87-0 N-0861 racemate

N-0861 racemate
(CAS: 121241-87-0)

N-0861 racemate is the racemate of N-0861 which appears to be an effective and selective A1 adenosine receptor antagonist in humans.

CAS 163838-04-8 UP202-56

UP202-56
(CAS: 163838-04-8)

UP202-56, an adenosine analogue, selectively acts via A1 receptors to significantly decrease noxiously-evoked spinal c-Fos protein expression.

CAS 890087-21-5 LUF 6000

LUF 6000
(CAS: 890087-21-5)

LUF6000 is an allosteric modulator of the human A3 adenosine receptor (AR). It was found to be an allosteric enhancer of Emax. It exerted an Emax-enhancing effe...

CAS 89705-21-5 N-[2-(4-Aminophenyl)ethyl]-adenosine

N-[2-(4-Aminophenyl)ethyl]-adenosine
(CAS: 89705-21-5)

N6-[2-(4-Aminophenyl)ethyl]adenosine is a potent, non-selective adenosine A3 adenosine receptor agonist. It could enhance the protective activity of carbamazepi...

CAS 870070-55-6 Tozadenant

Tozadenant
(CAS: 870070-55-6)

An orally administered, potent and selective inhibitor of the adenosine 2a (A2a) receptor

CAS 142344-87-4 GP531

GP531
(CAS: 142344-87-4)

GP531 is a novel riboside with similar structural and anti-ischemic properties to the adenosine-regulating agent (ARA) acadesine.

CAS 95523-13-0 N-[(4-Aminophenyl)methyl]adenosine

N-[(4-Aminophenyl)methyl]adenosine
(CAS: 95523-13-0)

N-[(4-Aminophenyl)methyl]adenosine is a adenosine receptor inhibitor with Ki value of 29 nM for Rat ecto-5′-Nucleotidase.

CAS 377727-87-2 Preladenant

Preladenant
(CAS: 377727-87-2)

Preladenant is a potent as Adenosine A2 receptor antagonists.

CAS 1202402-40-1 CPI-444

CPI-444
(CAS: 1202402-40-1)

CPI-444 is a potent, orally available, selective antagonist of the adenosine A2A receptor that has been well tolerated in Ph 1/1b studies in non-oncology indica...

SCH 58261
(CAS: 160098-96-4)

Potent, highly irreversible selective A2A antagonist

CAS 124555-18-6 GR 79236

GR 79236
(CAS: 124555-18-6)

GR 79236, an effective Adenosine A1 receptor agonist, could probably be used as an anti-inflammatory agent. IC50: 3.1 nM(Ki).

CAS 544417-40-5 Capadenoson

Capadenoson
(CAS: 544417-40-5)

Capadenoson is a potent and selective adenosine A1 receptor agonist, which is a powerful protective mechanism in cerebral.

FR-194921
(CAS: 202646-80-8)

FR-194921 is a potent, selective and orally active antagonist for central adenosine A1 receptors that displays high affinity and selectivity for the adenosine A...

Chemical Structure

CAS 89705-21-5 N-[2-(4-Aminophenyl)ethyl]-adenosine

Quick Inquiry

Verification code

Featured Items